Standard cancer treatments trigger immune responses that may influence tumor control.
The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in prostate cancer patients. This follow-up analysis was conducted to assess the relationship between autoantibody responses and clinical outcome. Patients with non-metastatic prostate cancer received external beam radiation therapy (EBRT) plus neoadjuvant and concurrent androgen deprivation. Treatment-induced autoantibodies were detected in almost a third of patients receiving combinatorial ADT and EBRT. Unexpectedly, patients that developed autoantibody responses to tumor antigens had a significantly lower 5-year biochemical failure-free survival (BFFS) than patients that did not develop an autoantibody response. Thus, tumor-reactive autoantibodies may be associated with increased risk of biochemical failure and immunomodulation to prevent autoantibody development may improve BFFS for select, high-risk prostate cancer patients receiving both ADT and EBRT.
Written by:
Johnson LD, Nesslinger NJ, Blood PA, Chima N, Richier LR, Ludgate C, Pai HH, Lim JT, Nelson BH, Vlachaki MT, Lum JJ. Are you the author?
Trev and Joyce Deeley Research Centre; Victoria, BC Canada; Radiation Oncology; BC Cancer Agency; Victoria, BC Canada; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada; Department of Medical Genetics; University of British Columbia; Vancouver, BC Canada; Radiation Oncology; BC Cancer Agency; Victoria, BC Canada; Department of Surgery; Division of Radiation Oncology; University of British Columbia; Vancouver, BC Canada.
Reference: Oncoimmunology. 2014 Jun 25;3:e29243.
doi: 10.4161/onci.29243
PubMed Abstract
PMID: 25114831